GSK press releases Follow Linerixibat accepted for priority review in China for cholestatic pruritus in patients with primary biliary cholangitis Submission based on data from positive GLISTEN phase III trial https://www.gsk.com/en-gb/media/press-releases/linerixibat-accepted-for-priority-review-in-china-for-cholestatic-pruritus-in-patients-with-primary-biliary-cholangitis/ gsk.com
